CN100424175C - ErbB-3 用于肿瘤治疗的方法和组合物 - Google Patents

ErbB-3 用于肿瘤治疗的方法和组合物 Download PDF

Info

Publication number
CN100424175C
CN100424175C CNB038067625A CN03806762A CN100424175C CN 100424175 C CN100424175 C CN 100424175C CN B038067625 A CNB038067625 A CN B038067625A CN 03806762 A CN03806762 A CN 03806762A CN 100424175 C CN100424175 C CN 100424175C
Authority
CN
China
Prior art keywords
erbb
amino acid
protein
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038067625A
Other languages
English (en)
Chinese (zh)
Other versions
CN1650011A (zh
Inventor
周明东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
ZESHENG SCIENCE AND TECHNOLOGY DEVELOPMENT Co Ltd SHANGHAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB02116259XA external-priority patent/CN1219882C/zh
Application filed by ZESHENG SCIENCE AND TECHNOLOGY DEVELOPMENT Co Ltd SHANGHAI filed Critical ZESHENG SCIENCE AND TECHNOLOGY DEVELOPMENT Co Ltd SHANGHAI
Publication of CN1650011A publication Critical patent/CN1650011A/zh
Application granted granted Critical
Publication of CN100424175C publication Critical patent/CN100424175C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB038067625A 2002-03-26 2003-03-26 ErbB-3 用于肿瘤治疗的方法和组合物 Expired - Fee Related CN100424175C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB02116259XA CN1219882C (zh) 2002-03-18 2002-03-26 以erbb－3为基础的用于肿瘤治疗的方法和组合物
CN02116259.X 2002-03-26
PCT/CN2003/000217 WO2003080835A1 (en) 2002-03-26 2003-03-26 Erbb3 based methods and compositions for treating neoplasms

Publications (2)

Publication Number Publication Date
CN1650011A CN1650011A (zh) 2005-08-03
CN100424175C true CN100424175C (zh) 2008-10-08

Family

ID=28048642

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038067625A Expired - Fee Related CN100424175C (zh) 2002-03-26 2003-03-26 ErbB-3 用于肿瘤治疗的方法和组合物

Country Status (7)

Country Link
US (2) US7919098B2 (enExample)
EP (2) EP2400021B1 (enExample)
JP (2) JP4660094B2 (enExample)
CN (1) CN100424175C (enExample)
AU (1) AU2003218600C1 (enExample)
CA (1) CA2480099C (enExample)
WO (1) WO2003080835A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
HRP20131113T1 (hr) * 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
WO2009157919A1 (en) * 2008-06-23 2009-12-30 Tumor Biology Investment Group, Inc. SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
BRPI0917871A2 (pt) * 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
CN102231987A (zh) * 2008-11-28 2011-11-02 上海泽生科技开发有限公司 纽兰格林和心脏干细胞
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
NO2719708T3 (enExample) 2009-11-13 2018-03-24
DK2516469T3 (en) 2009-12-22 2016-05-02 Roche Glycart Ag ANTI-HER3 antibodies and uses thereof
JP2013522237A (ja) 2010-03-11 2013-06-13 メリマック ファーマシューティカルズ インコーポレーティッド トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
TWI418362B (zh) * 2010-11-19 2013-12-11 Univ Nat Pingtung Sci & Tech 溶血性巴斯德桿菌重組外膜脂蛋白e及含此之疫苗組成物
JP2014508782A (ja) 2011-03-11 2014-04-10 メリマック ファーマシューティカルズ インコーポレーティッド ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用
CN103429262A (zh) 2011-03-15 2013-12-04 梅里麦克制药股份有限公司 克服对erbb途径抑制剂的抗性
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
US9956276B2 (en) * 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
WO2017014810A1 (en) * 2015-07-17 2017-01-26 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
EP3791891A1 (en) * 2014-07-17 2021-03-17 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP4368207A3 (en) 2015-09-02 2024-08-07 The Cleveland Clinic Foundation Ovarian cancer vaccines
CN108697779B (zh) 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
EP3512886B1 (en) * 2016-09-15 2025-06-11 Universität Stuttgart Antigen binding protein against her3
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
EP3688026A4 (en) * 2017-09-27 2021-11-10 L2 Diagnostics, LLC PHARMACEUTICAL AND VACCINAL COMPOSITIONS BASED ON PEPTIDE ERBB AND THEIR THERAPEUTIC USES FOR THE TREATMENT OF CANCER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008214A1 (en) * 1989-12-01 1991-06-13 The United States Of America, Represented By The Secretary, United States Department Of Commerce Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
AU645760B2 (en) 1989-08-04 1994-01-27 Berlex Laboratories, Inc. C-erbb-2 external domain: GP75
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5941868A (en) 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
PT896586E (pt) 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
DE69740038D1 (enExample) * 1996-07-12 2010-12-16 Genentech Inc
JP2001504326A (ja) 1996-10-18 2001-04-03 ジェネンテック インコーポレーテッド 抗ＥｒｂＢ２抗体
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
JP4515542B2 (ja) 1997-02-10 2010-08-04 ジェネンテック， インコーポレイテッド ヒレグリン変異体
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
US5962274A (en) 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
WO2001002600A2 (en) 1999-07-06 2001-01-11 General Atomics Detection of analytes using attenuated enzymes
MXPA02011194A (es) 2000-05-15 2003-03-10 Pharmacia Italia Spa Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales.
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
HRP20131113T1 (hr) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008214A1 (en) * 1989-12-01 1991-06-13 The United States Of America, Represented By The Secretary, United States Department Of Commerce Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5480968A (en) * 1989-12-01 1996-01-02 The United States Of America As Represented By The Department Of Health And Human Services Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto
US5820859A (en) * 1989-12-01 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of targeting a therapeutic agent to cells expressing the erb B-3 receptor
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies

Also Published As

Publication number Publication date
CA2480099A1 (en) 2003-10-02
WO2003080835A1 (en) 2003-10-02
US20110229478A1 (en) 2011-09-22
AU2003218600B2 (en) 2009-05-21
EP1495123A4 (en) 2009-06-24
US7919098B2 (en) 2011-04-05
CN1650011A (zh) 2005-08-03
EP1495123A1 (en) 2005-01-12
JP5249282B2 (ja) 2013-07-31
AU2003218600C1 (en) 2009-12-17
CA2480099C (en) 2019-01-08
JP4660094B2 (ja) 2011-03-30
US20080057064A1 (en) 2008-03-06
JP2010213710A (ja) 2010-09-30
JP2005533488A (ja) 2005-11-10
EP1495123B1 (en) 2013-10-30
AU2003218600A1 (en) 2003-10-08
EP2400021A3 (en) 2012-03-21
EP2400021B1 (en) 2016-11-30
EP2400021A2 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
CN100424175C (zh) ErbB-3 用于肿瘤治疗的方法和组合物
ES2675825T3 (es) Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2
US8470333B2 (en) Chimeric peptides comprising HER-2 B-cell epitopes and T-helper epitopes
JP4398644B2 (ja) ＥｒｂＢ界面ペプチド擬態およびその使用方法
PT1659178E (pt) Processo para a purificação ou produção de uma proteína mage
WO2010105573A1 (zh) 抗血管新生融合蛋白
US11235043B2 (en) Vaccines against antigens involved in therapy resistance and methods of using same
JP2010532656A (ja) 癌退縮抗原ｎｙ−ｅｓｏ−１およびｌａｇｅ−１を含む融合タンパク質
CN1798770B (zh) 用于治疗癌症的多聚肽体
WO2022100585A1 (zh) 抗Her-2抗体-趋化因子融合蛋白及其制法和应用
US10532090B2 (en) Vaccine composition and uses thereof
KR20090099011A (ko) 암의 치료를 위한 수술, 화학요법 또는 방사선요법과 조합된 면역요법에서 ｍａｇｅ ａ３－단백질 ｄ 융합 항원의 용도
CN114790248B (zh) MUC1-PDL1-IgG1 Fc肿瘤疫苗及其制备方法和应用
US11530242B2 (en) EGFRvIII immunogen and methods for using same
CN1444992A (zh) 以erbb－3为基础的用于肿瘤治疗的方法和组合物
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
WO2023077924A1 (zh) 一种抗胰腺癌的疫苗、及其医药用途
CN103539840A (zh) 表皮生长因子受体模拟表位肽及其应用
Antitumor A Chimeric Multi-Human Epidermal Growth
CN1919873A (zh) 包含人HSP70 ATPase结构域与哺乳动物p53蛋白的融合蛋白及其应用
HK1154591A (en) Anti-amyloid immunogenic compositions, methods and uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68

Patentee after: Zesheng Science and Technology Development Co., Ltd., Shanghai

Address before: Shanghai China

Patentee before: Zesheng Science and Technology Development Co., Ltd., Shanghai

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68

Patentee after: ZENSUN (SHANGHAI) SCI & TECH CO., LTD.

Address before: 201203 Shanghai Curie road in Pudong New Area Zhangjiang hi tech Park No. 68

Patentee before: Zesheng Science and Technology Development Co., Ltd., Shanghai

DD01 Delivery of document by public notice

Addressee: Jiang Zhenggang

Document name: Notice of termination of patent right

DD01 Delivery of document by public notice
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081008

Termination date: 20210326

CF01 Termination of patent right due to non-payment of annual fee